Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

References

• SamiiANuttJGRansomBRParkinson’s diseaseLancet20043639423 1783 179315172778
   PubMed Web of Science ®Google Scholar
• LewittPALevodopa for the treatment of Parkinson’s diseaseN Engl J Med200835923 2468 247619052127
   PubMed Web of Science ®Google Scholar
• ZádoriDKlivényiPToldiJFülöpFVécseiLKynurenines in Parkinson’s disease: therapeutic perspectivesJ Neural Transm (Vienna)20121192 275 28321858430
   PubMed Web of Science ®Google Scholar
• KlivényiPVécseiLNovel therapeutic strategies in Parkinson’s diseaseEur J Clin Pharmacol2010662 119 12519834698
   PubMed Web of Science ®Google Scholar
• ZádoriDSzalárdyLToldiJFülöpFKlivényiPVécseiLSome molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s diseaseJ Neural Transm (Vienna)20131204 673 68123196983
   PubMed Web of Science ®Google Scholar
• DézsiLVécseiLSafinamide for the treatment of Parkinson’s diseaseExpert Opin Investig Drugs2014235 729 742
   PubMed Web of Science ®Google Scholar
• ObálIMajláthZToldiJVécseiLMental disturbances in Parkinson’s disease and related disorders: the role of excitotoxinsJ Parkinsons Dis201442 139 15024346238
   PubMedGoogle Scholar
• RascolOPerez-LloretSFerreiraJJNew treatments for levodopa-induced motor complicationsMov Disord20153011 1451 146026293004
   PubMed Web of Science ®Google Scholar
• DevosDMoreauCOpicapone for motor fluctuations in Parkinson’s diseaseLancet Neurol2016152 127 128
   PubMed Web of Science ®Google Scholar
• OlanowCWSchapiraAHTherapeutic prospects for Parkinson diseaseAnn Neurol2013743 337 34724038341
   PubMed Web of Science ®Google Scholar
• WeinshilboumRMOtternessDMSzumlanskiCLMethylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferaseAnnu Rev Pharmacol Toxicol199939 19 5210331075
   PubMed Web of Science ®Google Scholar
• HauserRALevodopa: past, present, and futureEur Neurol2009621 1 819407449
   PubMed Web of Science ®Google Scholar
• KaakkolaSClinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s diseaseDrugs2000596 1233 125010882160
   PubMed Web of Science ®Google Scholar
• KhorSPHsuAThe pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s diseaseCurr Clin Pharmacol200723 234 24318690870
   PubMedGoogle Scholar
• GomesPSoares-da-SilvaPInteraction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cellsNeuropharmacology1999389 1371 138010471091
   PubMed Web of Science ®Google Scholar
• NuttJGWoodwardWRGancherSTMerrickD3-O-methyldopa and the response to levodopa in Parkinson’s diseaseAnn Neurol1987216 584 5883606046
   PubMed Web of Science ®Google Scholar
• GervasJJMuradásVBazánEAguadoEGde YébenesJGEffects of 3-OM-dopa on monoamine metabolism in rat brainNeurology1983333 278 2826681870
   PubMed Web of Science ®Google Scholar
• NissinenEMannistoPTBiochemistry and pharmacology of catechol-O-methyltransferase inhibitorsInt Rev Neurobiol201095 73 11821095460
   PubMed Web of Science ®Google Scholar
• GoncalvesDAlvesGSoares-da-SilvaPFalcãoABioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a reviewAnal Chim Acta2012710 17 3222123108
   PubMed Web of Science ®Google Scholar
• ScottLJOpicapone: a review in Parkinson’s diseaseDrugs20167613 1293 130027498199
   PubMed Web of Science ®Google Scholar
• FerreiraJJLeesARochaJFOpicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trialLancet Neurol2016152 154 165
   PubMed Web of Science ®Google Scholar
• KissLEFerreiraHSTorrãoLDiscovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferaseJ Med Chem2010538 3396 341120334432
   PubMed Web of Science ®Google Scholar
• RochaJFSantosAFalcãoAEffect of moderate liver impairment on the pharmacokinetics of opicaponeEur J Clin Pharmacol2014703 279 28624271646
   PubMed Web of Science ®Google Scholar
• BickerJAlvesGFortunaASoares-da-SilvaPFalcãoAA new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidatesInt J Pharm20165011–2 102 11126836708
   PubMed Web of Science ®Google Scholar
• KarhunenTTilgmannCUlmanenIJulkunenIPanulaPDistribution of catechol-O-methyltransferase enzyme in rat tissuesJ Histochem Cytochem1994428 1079 10908027527
   PubMed Web of Science ®Google Scholar
• PalmaPNBonifácioMJLoureiroAISoares-da-SilvaPComputation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstrate relative free energy calculationsJ Comput Chem2012339 970 98622278964
   PubMed Web of Science ®Google Scholar
• AlmeidaLRochaJFFalcãoAPharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitorClin Pharmacokinet2013522 139 15123248072
   PubMed Web of Science ®Google Scholar
• RochaJFAlmeidaLFalcãoAOpicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjectsBr J Clin Pharmacol2013765 763 77523336248
   PubMed Web of Science ®Google Scholar
• PintoRl’HostisPPatatAEvaluation of opicapone on cardiac repolarization in a thorough QT/QTc studyClin Pharmacol Drug Dev201546 454 46227137718
   PubMed Web of Science ®Google Scholar
• FalcãoARochaJFSantosAOpicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjectsClin Pharmacol Drug Dev201652 150 16127138028
   PubMed Web of Science ®Google Scholar
• BonifácioMJTorrãoLLoureiroAIPalmaPNWrightLCSoares-da-SilvaPPharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the ratBr J Pharmacol20151727 1739 175225409768
   PubMed Web of Science ®Google Scholar
• BonifácioMJTorraoLLoureiroAIWrightLCSoares-da-SilvaPOpicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitorParkinsonism Relat Disord201218suppl 2 S125
   Google Scholar
• BonifácioMJSutcliffeJSTorrãoLWrightLCSoares-da-SilvaPBrain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitorNeuropharmacology201477 334 34124148813
   PubMed Web of Science ®Google Scholar
• DingemanseJJorgaKMSchmittMIntegrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humansClin Pharmacol Ther1995575 508 5177768073
   PubMed Web of Science ®Google Scholar
• KeränenTGordinAKarlssonMInhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacaponeEur J Clin Pharmacol1994462 151 1578039535
   PubMed Web of Science ®Google Scholar
• RochaJFFalcãoASantosAEffect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrationsEur J Clin Pharmacol2014709 1059 107124925090
   PubMed Web of Science ®Google Scholar
• RochaJFFerreiraJJFalcãoAEffect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson diseaseClin Pharmacol Drug Dev201653 232 24027163503
   PubMed Web of Science ®Google Scholar
• FerreiraJJRochaJFFalcãoAEffect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s diseaseEur J Neurol2015225 815 82525649051
   PubMed Web of Science ®Google Scholar
• DeaneKHSpiekerSClarkeCECatechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s diseaseCochrane Database Syst Rev20044 CD004554
   Google Scholar
• LeesAFerreiraJJCostaREfficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson’s disease patients: BIPARK-II study [abstract no. 1038]J Neurol Sci2013333suppl 1 e116
   Google Scholar
• LopesNFerreiraJLeesAHepatic safety of opicapone in Parkinson’s disease patientsMov Disord201530suppl 1 S101
   Google Scholar
• LopesNFerreiraJLeesAExploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s diseaseMov Disord201530suppl 1 S101
   Google Scholar
• LeesAFerreiraJReichmannHOnset and stabilization of treatment effects in fluctuating Parkinson’s disease patients: exploratory by-week efficacy analysis of pooled phase III studiesMov Disord201631suppl 2 S642
   PubMedGoogle Scholar
• LopesNFerreiraJLeesAExploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progressionMov Disord201631suppl 2 S642
   PubMedGoogle Scholar
• LeesAFerreiraJLopesNEfficacy and safety of opicapone in patients over 70 years with Parkinson’s disease and motor fluctuationsMov Disord201530suppl 1 S99
   Google Scholar
• FerreiraJLeesATolosaESwitching double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK IMov Disord201631suppl 2 S633
   Google Scholar
• FerreiraJLeesARascolOActivities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease treated with opicaponeMov Disord201631suppl 2 S643
   Google Scholar
• CostaROliveiraCPintoROne-year open-label efficacy and safety of opicapone in Parkinson’s disease BIPARK-II studyMov Disord201429suppl 1 S233
   Google Scholar
• LeesAFerreiraJCostaR1-year safety of opicapone in patients with Parkinson’s disease and motor fluctuationsMov Disord201530suppl 1 S99
   Google Scholar
• LopesNFerreiraJLeesAEvaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatmentMov Disord201631suppl 2 S643
   Google Scholar
• PintoRVaz-da-SilvaMLopesNCardiac safety of opicapone in patients with Parkinson’s disease: analysis of the centralized phase III ECG datasetMov Disord201530suppl 1 S112
   Google Scholar
• DingemanseJIssues important for rational COMT inhibitionNeurology20005511 suppl 4 S24 S27 Discussion S28–S3211147507
   PubMed Web of Science ®Google Scholar
• KeatingGMLyseng-WilliamsonKATolcapone: a review of its use in the management of Parkinson’s diseaseCNS Drugs2005192 165 18415697329
   PubMed Web of Science ®Google Scholar
• AssalFSpahrLHadengueARubbia-BrandtLBurkhardPRTolcapone and fulminant hepatitisLancet19983529132 958
   Web of Science ®Google Scholar
• ColosimoCThe rise and fall of tolcaponeJ Neurol199924610 880 88210552233
   PubMed Web of Science ®Google Scholar
• Movement Disorder SocietyManagement of Parkinson’s disease: an evidence-based reviewMov Disord200217suppl 4 S1 S166
   Google Scholar
• European Medicines Agency [homepage on the Internet]Ongentys 25 mg Hard Capsules: Summary of Product Characteristics2016 Available from: http://www.ema.europa.euAccessed October 12, 2016
   Google Scholar
• StocchiFRascolOKieburtzKInitiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD studyAnn Neurol2010681 18 2720582993
   PubMed Web of Science ®Google Scholar
• SantosAFerreiraJLeesASafety of opicapone in fluctuating Parkinson’s disease patients: results of the 1-year extension of study BIPARK IMov Disord201631suppl 2 641
   Google Scholar